Summary of the Conference Call for Sanxin Medical Company Overview - **Company**: Sanxin Medical - **Industry**: Blood purification and dialysis products Key Points Financial Performance - In the first half of 2025, Sanxin Medical achieved revenue of 760 million yuan, a year-on-year increase of 10.83% [4] - Net profit attributable to shareholders was 115 million yuan, up 8.35% year-on-year [4] - Blood purification products contributed 626 million yuan in revenue, growing 20% and accounting for 82% of total revenue [4] - Revenue from drug delivery devices decreased by 15% year-on-year, totaling 82.4 million yuan [4] Market Expansion - Export revenue in the first half of 2025 reached 187 million yuan, a 67% increase year-on-year, with dialysis equipment and consumables making up 88% of exports [4][2] - The company is focusing on expanding into Southeast Asia, with plans to enter markets in Brazil, Turkey, and India [2][5] Product Development and Strategy - Sanxin Medical plans to issue convertible bonds to improve asset structure and expand production capacity, with approximately 4 billion yuan allocated for production expansion and 1.3 billion yuan for working capital [6] - The company aims to increase market share through capacity expansion and the promotion of new products like wet membrane dialyzers [3][21] Domestic Market Dynamics - The company’s market share for dialysis devices increased to approximately 8%, with device revenue growing about 70% year-on-year [7] - The number of patients receiving standardized blood dialysis treatment reached 1.027 million, with an expected growth rate of over 10% in the future [11] - The National Medical Insurance Administration's reforms have positively impacted the industry, enhancing patient and hospital engagement [12] Competitive Landscape - Sanxin Medical's market share for dialysis devices has grown from 5-6% to around 8%, driven by increased domestic production and market reshuffling [16] - The company faces challenges from price reductions due to centralized procurement and increased competition [21] Future Outlook - The company expects a revenue growth of around 10% for the full year 2025, despite pressures from centralized procurement and competition [3][21] - New product launches, including artificial blood vessels and wet membrane dialyzers, are planned for the second half of the year [6][10] International Market Insights - The company has gained market access in Indonesia, Mexico, and Peru, with plans for further expansion in Brazil, India, Vietnam, and Turkey [8] - The majority of exports are concentrated in Southeast Asia, with ASEAN countries accounting for nearly 70% of total exports [13] Regulatory and Policy Impact - The introduction of the CA deduction project by the National Medical Insurance Bureau is expected to create a favorable environment for the industry’s long-term development [12] Shareholder Returns - Sanxin Medical has proposed a mid-year dividend plan, aiming for a dividend payout ratio of 70% for the year [25] Conclusion - Sanxin Medical is positioned for growth in the blood purification sector, with a focus on expanding its product line and market presence while navigating challenges from competition and regulatory changes [25]

据证券之星公开数据整理，近期三鑫医疗(300453)发布2025年中报。根据财报显示，三鑫医疗营收净利 润同比双双增长。截至本报告期末，公司营业总收入7.61亿元，同比上升10.83%，归母净利润1.15亿 元，同比上升8.35%。按单季度数据看，第二季度营业总收入4.0亿元，同比上升12.65%，第二季度归母 净利润6139.24万元，同比上升16.65%。 本次财报公布的各项数据指标表现尚佳。其中，毛利率34.97%，同比减0.34%，净利率16.72%，同比减 0.54%，销售费用、管理费用、财务费用总计9480.45万元，三费占营收比12.46%，同比减3.58%，每股 净资产2.58元，同比增8.45%，每股经营性现金流0.36元，同比增38.2%，每股收益0.22元，同比增7.92% | 项目 | 2024年中报 | 2025年中报 | 同比增幅 | | --- | --- | --- | --- | | 营业总收入(元) | 6.86亿 | 7.61亿 | 10.83% | | 归母净利润(元) | 1.06亿 | 1.15亿 | 8.35% | | 扣非净利润(元) | 9448.35万 | ...

证券代码：300453 证券简称：三鑫医疗 江西三鑫医疗科技股份有限公司 投资者关系活动记录表 | 编号：20250521 | | --- | | | □特定对象调研 □分析师会议 | | --- | --- | | 投资者关系活动 | □媒体采访 □业绩说明会 | | | □新闻发布会 □路演活动 | | 类别 | □现场参观 | | | ☑其他 2025 年江西辖区上市公司投资者网上集体接待日活动 | | 参与单位名称 | 参与2025年江西辖区上市公司投资者网上集体接待日活动的投资者 | | 时间 | 2025年5月21日 | | 地点 | 全景网"投资者关系互动平台"（https://ir.p5w.net） | | 上市公司接待 | 董事长彭义兴 | | 人员姓名 | 董事、副总裁、董事会秘书、代理财务总监 刘明 | | | 问：公司今年上半年销售情况如何？公司今年有参加多少展会的准 | | | 备？公司目前在境外的销售是否良好？另外公司在美国几乎没有业务， | | | 是否考虑开拓美国市场？ | | | 答：公司目前生产经营情况正常，公司将在《2025 年半年度报告》 | | | 中披露今年上半年的 ...

Core Viewpoint - Sanxin Medical has achieved significant growth and transformation over the past decade, marking its 10th anniversary since its IPO on the Shenzhen Stock Exchange, with a strategic shift from traditional infusion and injection to blood purification, leading to a substantial increase in revenue from blood purification products [1][2]. Financial Performance - Total revenue increased from 312 million yuan in 2015 to 1.5 billion yuan in 2024, with a compound annual growth rate (CAGR) of 19.07% [2]. - Net profit attributable to shareholders rose from 52 million yuan in 2015 to 227 million yuan in 2024, with a CAGR of 17.85% [2]. - In the last five years, revenue and net profit CAGR reached 15.76% and 29.82%, respectively [2]. Profitability and Returns - The company's gross profit margin reached a record high of 35.33% in 2024 [5]. - By the end of 2024, net assets totaled 1.324 billion yuan, a 4.3-fold increase compared to ten years ago [5]. - Sanxin Medical has distributed cash dividends 11 times since its IPO, totaling 495 million yuan, which is 2.15 times the net amount raised during the IPO; the dividend for 2024 amounted to 156 million yuan, with a payout ratio of 68.77% and an annual dividend yield of 4.17% [5]. Strategic Initiatives - The company is focusing on product innovation and capitalizing on national procurement opportunities while breaking into overseas markets to expand its domestic and international market share [5]. - Sanxin Medical has initiated a global expansion strategy, successfully registering products in countries such as Indonesia, Peru, and Mexico, and is advancing certification processes in Russia and Turkey [5].

文/梧桐晓编 2025年1-3月，沪、深、北三个交易所共受理IPO申报企业只有8家，其中上交所2家，都是科创板，深交所受理1家，申报主板，北交所受理5家。其中申报科创板 IPO的昂瑞微电子报告期累计亏损8.8亿元。申报深交所主板上市的华润新能源为一家设立于中国香港红筹企业，2023年扣非净利润高达82亿元。北交所受理的5 家公司选择的具体上市标准均为《上市规则》第 2.1.3 条第一项：预计市值不低于 2 亿元，最近两年净利润均不低于 1500 万元且加权平均净资产收益率平均不低 于 8%，或者最近一年净利润不低于 2500 万元且加权平均净资产收益率不低于 8%。 8家今年一季度受理的IPO申报企业基本信息 单位：亿元 | 公司简称 | 甲报板块 | 王营业务 | 最近一年 | 最近一年 | 保荐机构 | | --- | --- | --- | --- | --- | --- | | | | | 营收 | 净利润 | | | 昂瑞微电子 | 科创板 | 射频前端芯片、射频SoC芯片及其他模拟芯片的研发设计 | 21.01 | -1.1003 | 中信建投 | | | | 与销售 | | | | | 傲拓科技 ...